Home Cart Sign in  
Chemical Structure| 24502-78-1 Chemical Structure| 24502-78-1

Structure of Acetylshikonin
CAS No.: 24502-78-1

Chemical Structure| 24502-78-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Acetyl shikonin, a natural product isolated and purified from the roots of Lithosperraum erythrorhizon Sieb. et Zucc., inhibits the generation of NADPH oxidase complex in the activation of respiratory burst of PMNs, but does not directly inhibit the activity of NADPH oxidase already generated, and is a non-selective cytochrome P450 inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Acetylshikonin

CAS No. :24502-78-1
Formula : C18H18O6
M.W : 330.33
SMILES Code : CC(=O)O[C@H](CC=C(C)C)C1=CC(=O)C2=C(C(O)=CC=C2O)C1=O
MDL No. :MFCD00143538

Safety of Acetylshikonin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT-15 0, 2.5, 5, 10 μM 24, 48, 72 h Suppressed cell proliferation by inducing G1 phase cell cycle arrest and apoptosis PMC7174886
HCT-116 0, 2.5, 5, 10 μM 24, 48, 72 h Suppressed cell proliferation by inducing G2 phase cell cycle arrest and apoptosis PMC7174886
SW 620 0, 2.5, 5, 10 μM 24, 48, 72 h Suppressed cell proliferation by inducing G3 phase cell cycle arrest and apoptosis PMC7174886
DLD-1 0, 2.5, 5, 10 μM 24, 48, 72 h Suppressed cell proliferation by inducing G4 phase cell cycle arrest and apoptosis PMC7174886
Lung single cells 0.6, 1.25, 2.5 μM 12 h Acetylshikonin down-regulated the production of IL-6 in a dose-dependent manner, with significant reduction at 2.5 μM concentration. PMC9610350
BMDM cells 0.6, 1.25, 2.5 μM 12 h Acetylshikonin down-regulated the production of IL-6 in a dose-dependent manner, with significant reduction at 2.5 μM concentration. PMC9610350
RAW264.7 cells 0.6, 1.25, 2.5 μM 12 h Acetylshikonin down-regulated the production of IL-6 in a dose-dependent manner, with significant reduction at 2.5 μM concentration. PMC9610350
MEF cells and MEF Nur77−/− cells 10 µM 24 h SK07 induced apoptosis in MEF cells, but its effect was significantly reduced in Nur77 knockout cells. PMC2679687
HeLa cervical cancer cells 5 or 10 µM 12 or 24 h Acetylshikonin and its analog SK07 significantly increased Nur77 protein levels in HeLa cells. PMC2679687
NIH-H460 lung cancer cells 5 or 10 µM 12 or 24 h Acetylshikonin and its analog SK07 significantly increased Nur77 protein levels, while SK06 had a weaker effect. PMC2679687
mouse Lewis lung carcinoma cell line LLC 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 μg/ml 48 h Acetylshikonin inhibited the growth of LLC cells in a dose-dependent manner with IC50 of 2.72 ± 0.38 μg/ml. PMC2717966
human breast adenocarcinoma cell line MCF-7 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 μg/ml 48 h Acetylshikonin inhibited the growth of MCF-7 cells in a dose-dependent manner with IC50 of 3.04 ± 0.44 μg/ml. PMC2717966
human hepatocellular carcinoma cell line Bel-7402 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 μg/ml 48 h Acetylshikonin inhibited the growth of Bel-7402 cells in a dose-dependent manner with IC50 of 6.82 ± 1.5 μg/ml. PMC2717966
human lung adenocarcinoma cell line A549 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 μg/ml 48 h Acetylshikonin inhibited the growth of A549 cells in a dose-dependent manner with IC50 of 5.6 ± 0.86 μg/ml. PMC2717966
Rat neutrophils 0.48 ± 0.03 μM 3 min Acetylshikonin inhibited fMLP/CB-induced superoxide anion generation and oxygen consumption with IC50 values of 0.48 μM and 0.39 μM, respectively. PMC1564703
Rat neutrophils 0.39 ± 0.03 μM 3 min Acetylshikonin inhibited PMA-induced superoxide anion generation and oxygen consumption with IC50 values of 0.48 μM and 0.39 μM, respectively. PMC1564703
U87 human GBM cells 1.5 μM 72 h To evaluate the cytotoxic effects of Acetylshikonin on U87 cells, results showed that all concentrations of ASH induced significant cell death. PMC9953749
U251 human GBM cells 1.5 μM 72 h To evaluate the cytotoxic effects of Acetylshikonin on U251 cells, results showed that all concentrations of ASH induced significant cell death. PMC9953749
THP-1 cells 0.3125–5 µM 24 h Acetylshikonin significantly inhibited the proliferation of THP-1 cells. PMC8899184
K562 cells 0.3125–5 µM 24 h Acetylshikonin significantly inhibited the proliferation of K562 cells. PMC8899184
HL-60 cells 0.3125–5 µM 24–48 h Acetylshikonin significantly inhibited the proliferation and viability of HL-60 cells and induced apoptosis through the mitochondrial pathway, while promoting S-phase cell cycle arrest. PMC8899184

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Ba/F3 EGFR ASV and L861Q allografts model Oral 20 and 40 mg/kg Once daily for 13 days Evaluate the inhibitory effect of Almonertinib on tumor growth with EGFR ASV and L861Q mutations PMC7174886
BALB/c mice Acute lung injury model Intragastric administration 300 mg/kg Three consecutive days Acetylshikonin significantly decreased the concentrations of IL-6, TNF-α and IL-1α in BALF and suppressed symptoms of interstitial pneumonia in a concentration-dependent manner. PMC9610350
C57BL/6 mice Lewis lung carcinoma model Intraperitoneal injection 0.5, 1, 2 mg/kg Once every two days, six times in total Acetylshikonin (2 mg/kg) suppressed LLC tumor growth with an inhibition rate of 42.85%. Immunohistochemical staining showed increased expression of bax and caspase-3 and decreased expression of bcl-2 in acetylshikonin groups. PMC2717966

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.03mL

0.61mL

0.30mL

15.14mL

3.03mL

1.51mL

30.27mL

6.05mL

3.03mL

References

 

Historical Records

Categories